Rest of the world
Outside of Europe and the USA, we continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure.
We are also taking our own steps to expand our reporting of payments to individual HCPs as part of our commitment to transparency and responsible disclosure. Beginning in 2019, we will, where legally permitted, disclose annually individual level payments for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards in major developed markets in Asia and North America, alongside Europe and the US. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
Find out more
We were one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians
We fully support the EFPIA's Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations
Compassionate use (Expanded access)
Our policy explains our position and criteria for assessing requests and provides a link for health care professionals’ requests.
We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products